Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma.

Pinato, David J; Valeri, Nicola; Muhammed, Ambreen; Cortellini, Alessio

Pinato, David J; Valeri, Nicola; Muhammed, Ambreen; Cortellini, Alessio.

Afiliação

Pinato DJ; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London W12 0HS, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk.
Valeri N; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London W12 0HS, UK; Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden NHS Trust, London, UK.
Muhammed A; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London W12 0HS, UK.
Cortellini A; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London W12 0HS, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Lancet Gastroenterol Hepatol ; 6(7): 515-516, 2021 07.

Article em En | MEDLINE | ID: mdl-33971142

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Vírus da Hepatite B; Humanos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Lancet Gastroenterol Hepatol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google